Articles tagged with Breast Cancer
A new study suggests that early-stage triple-negative breast cancer (TNBC) patients with high levels of immune cells in their tumors may have a lower risk of recurrence and better survival rates even without chemotherapy. Higher TILs in breast cancer tissue were associated with lower recurrence rates among participants.
A study published in Nature Genetics reveals early cell changes in healthy carriers of BRCA1 and BRCA2 gene mutations, suggesting a potential target for breast cancer prevention. The researchers created the world's largest catalogue of human breast cells, which may lead to the use of existing immunotherapy drugs as an early intervention.
Researchers assessed the feasibility of dual PD-L1/CTLA-4 checkpoint inhibition in Stage II or III hormone receptor-positive, HER2-negative breast cancer. Eight patients received upfront durvalumab and tremelimumab prior to neoadjuvant chemotherapy, showing mixed responses and limited benefit.
Researchers at the University of Toronto have found that two enzymes, APOBEC3C and APOBEC3D, promote resistance to chemotherapy drug gemcitabine in pancreatic cancer cells. Removing these enzymes can kill cancer cells by stymieing DNA repair.
A team of researchers from Hiroshima University has discovered a molecule called AIbZIP that promotes the production of cancer cells in triple-negative breast cancer. This finding may lead to new therapeutic targets for the treatment of this aggressive form of breast cancer.
A new study suggests that tailored treatment can predict the response of breast cancer patients to chemotherapy, allowing for safe omission of extensive lymph node removal. The MARI protocol showed a 95% overall survival rate and 89% disease-free survival rate in patients who achieved pathological complete response.
Scientists from UC3M and Johns Hopkins University have developed a computational model that simulates the invasion process of cancer cells based on the characteristics of surrounding tissue and cell junctions. The model allows for predicting tumor evolution in patients by analyzing mechanical properties of the microenvironment.
A combined PET-MRI scan improved treatment outcomes for 57 out of 205 patients with early-stage breast cancer. The scan helped doctors spot signs of tumour spread, enabling alternative treatments such as chemotherapy or different surgical approaches.
A new AI tool can predict which breast cancer patients are at risk of chronic arm swelling after surgery and radiotherapy. The tool, developed by international researchers, uses machine learning algorithms to analyze patient data and provides easily understandable explanations for doctors and patients.
Adding ribociclib to hormone therapy improves invasive disease-free survival by 90.4% at three years, distant disease-free survival by 90.8%, and recurrence-free survival by 91.7%. The study found a 25% relative reduction in recurrence rate for patients with stage 2 or 3 HR-positive, HER2-negative early breast cancer.
Researchers found that young breast cancer patients who received a low-dose radiotherapy boost had a lower risk of local recurrence after 10 years, with only 4.4% experiencing recurrence. In contrast, high-dose boosts resulted in fewer recurrences but also more severe fibrosis and cosmetic issues.
A new genetic test has identified patients with triple negative early-stage breast cancer who are unlikely to respond to immunotherapy drugs. The test, called ImPrintTN, can predict a patient's likelihood of responding to these treatments and help avoid severe side effects.
Researchers have developed a new AI model, AsymMirai, to predict 5-year breast cancer risk from mammograms. The model performs almost as well as the state-of-the-art Mirai, but with an interpretable reasoning process, making it a valuable adjunct to human radiologists.
New data show that adding pembrolizumab to chemotherapy before and after surgery for breast cancer leads to better outcomes, with significant increases in pathological complete response rates across all age groups. The study also found similar rates of breast-conserving surgery and mastectomy, as well as lower residual cancer burdens.
A clinical trial found that breast tomosynthesis reduces interval breast cancer by 49%, making it a valuable tool for early detection. The test also detects smaller tumors and improves prognosis.
A randomized controlled trial found that exercise programmes reduced fatigue and improved quality of life for patients with metastatic breast cancer. The study showed the greatest benefit among younger patients, but also suggested that supervised exercise can be beneficial for all patients with advanced disease.
A new review by UMass Amherst researchers highlights the need for more research on breast cancer cell dormancy, which is a contributing factor to metastatic breast cancer. The study aims to identify gaps in research and develop better models to understand and treat this phenomenon.
The ALEXANDRA/IMpassion030 phase 3 trial found that adding atezolizumab to chemotherapy after surgery did not improve survival for early-stage triple-negative breast cancer patients. Researchers also found no benefit in different sub-groups, such as those with lymph node spread and PD-L1 positive cancer.
The study found a significant decrease in newly diagnosed breast cancer cases, with the largest declines seen among women aged 50-69 and Hispanic women. The results have implications for how physicians and policymakers address issues related to diagnostic delays during the pandemic.
Researchers developed a GPS nanoparticle platform that can home in on cancer cells to deliver gene-editing tools, targeting the protein implicated in tumor growth and spread. The technique may offer a more precise and effective treatment for notoriously hard-to-treat basal-like breast cancers.
A study found that up to 87% of childhood cancer survivors are not following recommended screening guidelines, leaving them vulnerable to late effects such as heart disease and certain cancers. The lack of awareness and barriers to adherence may contribute to this low rate, highlighting the need for improved support and education.
Researchers at the University of Cincinnati Cancer Center have identified a new protein called p47 that helps prevent breast cancer metastasis. The study found that lower p47 expression was correlated with higher breast cancer metastasis, and that increasing p47 function could potentially lead to new therapies.
Researchers have designed a candidate drug to target the K-Ras G12D mutation, responsible for nearly half of all pancreatic cancer cases. The molecule permanently modifies the mutation, stopping tumor growth in cancer cell lines and animal models.
Researchers investigated combining Sacituzumab govitecan with platinum-based chemotherapeutics for triple-negative breast cancer, urinary bladder carcinoma, and small-cell lung carcinoma. The study showed additive to synergistic antitumor effects in vitro and in vivo, with improved outcomes in tumor-bearing animals.
A study from Florida Atlantic University identifies key social factors contributing to low breast cancer screening rates in the US. Socioeconomic status, access to healthcare, and insurance status are among the top influencers of breast cancer screening behavior.
Researchers deciphered the male breast cancer genome, identifying gene mutations and molecular profiles that could impact diagnosis and treatment. The study found mutations in genes known to drive cancer growth and structural variants impacting other cancer-associated genes.
The NCI-MATCH precision medicine trial discovered that trastuzumab-pertuzumab, approved for HER2-positive breast cancer, can shrink tumors in patients with other types of cancer and high levels of the HER2 gene. The study found a 12% confirmed overall response rate, with partial responses in various cancers.
A study published in JAMA Oncology found that MRI monitoring in women with BRCA1 mutations significantly reduces breast cancer mortality without the need for preventive mastectomy. The research included data from 2,488 women and showed a notable decrease in mortality rate among participants.
Researchers identified a putative paclitaxel response predictive biomarker for glioblastoma and breast cancer using the whole genome CRISPR knockout screen. The biomarker candidate was validated in two independent breast cancer patient cohorts that received taxane treatment.
A new study published in Radiology found that annual breast cancer screening beginning at age 40 and continuing until 79 results in the highest mortality reduction. The study analyzed Cancer Intervention and Surveillance Modeling Network (CISNET) estimates and showed that annual screening reduces breast cancer deaths by 41.7%.
Researchers at Tohoku University have developed a novel monoclonal antibody targeting HER2-positive breast cancer cells, providing a new tool for treating this aggressive subtype. The antibody disrupts cell growth and proliferation while minimizing harm to surrounding healthy tissue.
A study co-led by Prof. Kelly Metcalfe finds risk-reducing mastectomies significantly reduce breast cancer risk and death probability in women with a BRCA1 or BRCA2 genetic variant. The procedure reduces the risk of breast cancer by 80% and decreases mortality to less than 1%.
A new hand-held device screens for breast cancer biomarkers from a tiny spit sample, offering quick and efficient results. The portable tool distinguishes between healthy tissue, early cancer, and advanced cancer in a small group of women.
Researchers analyze how companies use feminist narratives to promote unscientific tests and treatments for women, often with uncertain effectiveness. This marketing behavior risks harming women, contributing to overdiagnosis and overtreatment.
A novel three-drug combination of an HDAC inhibitor with two types of immunotherapy achieved a 25% overall response rate and 50% progression-free survival in women with advanced HER2-negative breast cancer. Patients with triple-negative breast cancer had a higher response rate, highlighting the need for further clinical evaluation.
A new study has identified a genetic marker that can predict which patients are likely to respond to immunotherapy in various types of cancer. Tumors with high intragenic rearrangement (IGR) burden, which indicates cryptic structural rearrangements of the genetic code, may respond better to immunotherapy.
Researchers have developed a hand-held biosensor that can detect breast cancer biomarkers from saliva with high accuracy and efficiency. The device is portable, reusable, and cost-effective, making it an excellent choice for communities or hospitals without access to advanced technologies like MRI.
Researchers developed a compact, cost-effective PA sensing instrument for biomedical tissue diagnosis, showcasing its potential to streamline sampling processes and improve diagnostic accuracy for breast disease. The instrument successfully differentiated various tissue types based on quantitative spectral parameters.
Researchers at the University of Adelaide have discovered a new approach to defeating breast cancer by stimulating the androgen receptor. The study found that enobosarm was effective against estrogen receptor-positive breast cancer, which is the most common form of the disease.
A novel imaging technique, low-dose positron emission mammography (PEM), shows promise in transforming breast cancer detection by providing high sensitivity and low false positive rates. PEM could potentially decrease healthcare costs and reduce unnecessary procedures for patients with dense breasts.
A new study published in The Lancet Oncology demonstrates that the drug enobosarm has anti-tumour effects in oestrogen receptor positive breast cancer patients, providing a novel approach to treatment. The study showed that enobosarm was well tolerated with no significant impact on quality of life.
Researchers have developed a new treatment combining immunotherapy with lab-cultivated T-cells from patients' blood, which significantly inhibits triple-negative breast cancer growth and metastasis. The treatment has shown promising outcomes in animal models, but further testing in humans is needed to confirm its effectiveness.
Rates of re-excision after initial breast-conserving surgery remain high across the US, leading to increased healthcare costs and a higher risk of postoperative complications. The study found that younger age and ductal carcinoma in situ are associated with a higher reoperation rate.
A new study shows that inhibiting TACC3 can restore the effectiveness of T-DM1 in HER2-positive breast cancer cells, which have developed resistance. This is achieved by inducing immunogenic cell death and enhancing the response to the drug.
A global study has identified evidence-based approaches to prevent breast cancer-related arm lymphoedema (BCRAL) by addressing risk factors and implementing surveillance programs. The research provides a clinical guide for healthcare teams worldwide to adopt a proactive approach in preventing this irreversible complication.
Scientists at the Garvan Institute of Medical Research have identified unique DNA methylation patterns in phyllodes tumours, allowing for accurate diagnosis and distinction from other cancers. The discovery could lead to improved diagnosis and treatment options for patients with this rare disease.
Researchers identified SMYD2 as a key player in breast cancer metastasis, enabling the development of early treatments. Inhibiting SMYD2 inhibits BCAR3 activity, blocking metastatic cell migration and invasion.
A team led by UCF College of Nursing Professor Victoria Loerzel developed an innovative educational game for older adults with cancer, simulating symptoms and self-management. The game was successful in increasing the use of preventative strategies among participants, reducing symptom severity and hospital admissions.
Cancer kills more Black people than White individuals in the Barretos region, whereas in São Paulo city, it is the opposite, according to a study published in Cancer Causes & Control. The disparity is most pronounced for breast and cervical cancer among Black women.
A study found that the 21-gene breast recurrence score test may underestimate chemotherapy benefits for young Black women with estrogen receptor-positive breast cancer. The researchers recommend lowering the test's cutoff point to ensure accurate treatment recommendations for all patients regardless of race or ethnicity.
Experts predict a significant increase in bowel cancer death rates among young adults in the EU and UK, driven by rising obesity and heavy alcohol consumption. Death rates are predicted to rise by 26% in men and nearly 39% in women in the UK, with similar increases seen in Italy and other European countries.
The study found a surge in breast cancer diagnoses among women under 50, with steeper increases in recent years. Estrogen-receptor positive tumors, fueled by estrogen, are driving the rise.
Researchers at Rice University have discovered a promising new immunological pathway to treat stubborn bone tumors in breast cancer patients. The glyco-immune checkpoint axis, involving protein Siglec-15, plays a crucial role in hiding bone tumors from the immune system.
A recent study published in Cell Reports reveals that cancer cells can prevent the immune system from attacking them by inhibiting key checkpoints. Researchers found that monotherapy agents targeting these checkpoints may not be effective without an inflammatory trigger, explaining why some immunotherapies work while others fail.
A recent study published in The BMJ found that women diagnosed with ductal carcinoma in situ (DCIS) outside the NHS breast screening programme are four times more likely to develop invasive breast cancer and die from breast cancer. The increased risk lasts for at least 25 years after diagnosis, suggesting longer-term monitoring is needed.
Stacyann Bailey studies how cancer treatment affects bones, hoping to prevent fractures and improve patient outcomes. Up to 50% of patients with metastatic bone disease develop fractures due to treatment, making her work crucial for their quality of life.
Researchers at Insilico Medicine have identified MYT1 as a promising therapeutic target for breast and gynecological cancers. A series of novel, potent, and highly selective inhibitors specifically targeting MYT1 were discovered using AI-driven generative biology and chemistry engine.
A groundbreaking study identifies FAM3C as a key regulator of breast cancer progression within the tumor microenvironment. The overexpression of FAM3C promotes breast cancer cell survival and metastasis, while its depletion inhibits tumor growth in genetically engineered mouse models.
Researchers at Cleveland Clinic have developed a peptide therapeutic that blocks aggressive cancer cells from multiplying rapidly. The treatment disrupts the molecular processes behind cancer growth and induces tumor cell death, making it a promising new strategy for treating triple-negative breast cancer.
A Stanford Medicine-led study found that advances in treating metastatic breast cancer are responsible for nearly one-third of the decrease in annual deaths from breast cancer between 1975 and 2019. This decline is attributed to improved treatments, which have enabled women with metastatic disease to live longer than ever.